Editas Medicine, Inc. Stock Analysis & AI Score
Editas Medicine, Inc. (EDIT) has an ST Score of 45.9 (C+), driven by its Forecast (A) and held back by its Financial Strength (D). Analysts rate it Buy with a $4.50 price target (+63.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Editas Medicine, Inc. (EDIT) has an ST Score of 45.9 (C+), driven by its Forecast (A) and held back by its Financial Strength (D). Analysts rate it Buy with a $4.50 price target (+63.6% upside).
- Strongest
- ForecastA
- Weakest
- Financial StrengthD
All factor grades
- ForecastA
- MomentumB-
- ValuationC+
- ProfitabilityC
- GrowthC
- Financial StrengthD
- Piotroski3/9
Contact
EDIT stock: frequently asked questions
What is EDIT's ST Score?
Editas Medicine, Inc. (EDIT) has an ST Score of 45.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EDIT a buy, hold, or sell?
Analysts rate EDIT a Buy, with a price target of $4.50 (+63.6% vs the current price). Our ST Score grades it C+ (45.9/100). The ST Score is a data-driven signal, not a recommendation.
What are EDIT's factor grades?
Valuation C+, Profitability C, Financial Strength D, Momentum B-, Growth C, Forecast A.
What is EDIT's valuation grade?
Editas Medicine, Inc. (EDIT) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EDIT's growth grade?
Editas Medicine, Inc. (EDIT) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EDIT's profitability grade?
Editas Medicine, Inc. (EDIT) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EDIT's financial strength grade?
Editas Medicine, Inc. (EDIT) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EDIT?
The average analyst price target for Editas Medicine, Inc. (EDIT) is $4.50 from 26 analysts, which is +63.6% versus the recent price of $2.75.
What is EDIT's Piotroski score?
Editas Medicine, Inc. (EDIT) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.